Abstract:
The present invention provides a product (1) that includes a pharmaceutical unit dosage or diagnostic form (6) that includes at least one active ingredient that is present in an amount that advantageously does not vary by more than about five percent from a predetermined target amount. In one embodiment, the unit form comprises a substrate (8), a deposit (14) that is disposed on the substrate and a cover layer (9) that overlies the deposit and is joined to the substrate by a bond that encircles that deposit, thereby encapsulating it between the substrate and cover substrates. The deposit comprises a powder, at least some of which includes the at least one active ingredient. The unit form is created via a dry powder deposition apparatus that electrostatically deposits the powder on the substrate utilizing an electrostatic chuck and charged powder delivery apparatus.
Abstract:
A novel solid pharmaceutical dosage formulation of hydrophobic drugs is disclosed, which provides enhanced dissolution and improved bioavailability. The hydrophobic drug is deposited electrostatically on the base substrate. The dosage form may include any pharmaceutically acceptable additive, disposed within a carrier that is segregated from, but in contact with, the deposit. Figure No. 1 depicts an isometric view of a product comprising a strip package containing a plurality of unit forms in accordance with the prior art.
Abstract:
A novel solid pharmaceutical dosage formulation of hydrophobic drugs is disclosed, which provides enhanced dissolution and improved bioavailability. The hydrophobic drug is deposited electrostatically on the base substrate. The dosage form may include any pharmaceutically acceptable additive, disposed within a carrier that is segregated from, but in contact with, the deposit. Figure No. 1 depicts an isometric view of a product comprising a strip package containing a plurality of unit forms in accordance with the prior art.
Abstract:
Provided is, among other things, a conductive inlay film comprising; a layer of dielectric film (21) having a pattern of holes (23) suitable to define selected regions to which particles will be deposited by electrostatic deposition; and a conductive element (22) comprising polymer, which element comprises (a) a conductive film laminated (22) against the dielectric film (21) or (b) a conductive film embedded within the holes (23), the portion of the conductive element appearing within the holes comprising conductive inlays, wherein the conductive element (22) is adapted to contact one or mor e electrode pads and provide electrical potential at the selected regions, and wherein the dielectric film (21) electrically isolates the selected regions.
Abstract:
The present invention provides a product (1) that includes a pharmaceutical unit dosage or diagnostic form (6) that includes at least one active ingredient that is present in an amount that advantageously does not vary by more than about five percent from a predetermined target amount. In one embodiment, the unit form comprises a substrate (8), a deposit (14) that is disposed on the substrate and a cover layer (9) that overlies the deposit and is joined to the substrate by a bond that encircles that deposit, thereby encapsulating it between the substrate and cover substrates. The deposit comprises a powder, at least some of which includes the at least one active ingredient. The unit form is created via a dry powder deposition apparatus that electrostatically deposits the powder on the substrate utilizing an electrostatic chuck and charged powder delivery apparatus.
Abstract:
Provided is, among other things, a conductive inlay film comprising; a layer of dielectric film (21) having a pattern of holes (23) suitable to define selected regions to which particles will be deposited by electrostatic deposition; and a conductive element (22) comprising polymer, which element comprises (a) a conductive film laminated (22) against the dielectric film (21) or (b) a conductive film embedded within the holes (23), the portion of the conductive element appearing within the holes comprising conductive inlays, wherein the conductive element (22) is adapted to contact one or more electrode pads and provide electrical potential at the selected regions, and wherein the dielectric film (21) electrically isolates the selected regions.
Abstract:
The present invention provides a product (1) that includes a pharmaceutical unit dosage or diagnostic form (6) that includes at least one active ingredient that is present in an amount that advantageously does not vary by more than about five percent from a predetermined target amount. In one embodiment, the unit form comprises a substrate (8), a deposit (14) that is disposed on the substrate and a cover layer (9) that overlies the deposit and is joined to the substrate by a bond that encircles that deposit, thereby encapsulating it between the substrate and cover substrates. The deposit comprises a powder, at least some of which includes the at least one active ingredient. The unit form is created via a dry powder deposition apparatus that electrostatically deposits the powder on the substrate utilizing an electrostatic chuck and charged powder delivery apparatus.
Abstract:
A novel solid pharmaceutical dosage formulation of hydrophobic drugs is disclosed, which provides enhanced dissolution and improved bioavailability. The formulation comprises: a base substrate comprising a first polymer; a deposit, comprising a therapeutic amount of a hydrophobic drug, deposited on the base substrate; a cover substrate comprising a second polymer, the cover substrate covering the deposit and joined to the base substrate by a bond that encircles the deposit; and a dissolution-enhancing amount of a surfactant, disposed within a carrier that is segregated from, but in contact with, the deposit. In another embodiment, the dosage form may include any pharmaceutically acceptable additive, disposed within a carrier that is segregated from, but in contact with, the deposit. In a preferred embodiment, the hydrophobic drug is deposited electrostatically on the base substrate.
Abstract:
A novel solid pharmaceutical dosage formulation of hydrophobic drugs is disclosed, which provides enhanced dissolution and improved bioavailability. The hydrophobic drug is deposited electrostatically on the base substrate. T he dosage form may include any pharmaceutically acceptable additive, disposed within a carrier that is segregated from, but in contact with, the deposit. Figure No. 1 depicts an isometric view of a product comprising a strip packa ge containing a plurality of unit forms in accordance with the prior art.
Abstract:
Provided is, among other things, a conductive inlay film comprising; a layer of dielectric film (21) having a pattern of holes (23) suitable to define selected regions to which particles will be deposited by electrostatic deposition; and a conductive element (22) comprising polymer, which element comprises (a) a conductive film laminated (22) against the dielectric film (21) or (b) a conductive film embedded within the holes (23), the portion of the conductive element appearing within the holes comprising conductive inlays, wherein the conductive element (22) is adapted to contact one or more electrode pads and provide electrical potential at the selected regions, and wherein the dielectric film (21) electrically isolates the selected regions.